Subtyping of psychiatric disorders: implications for drug development

Psychiatric diagnosis suffers from being based on phenomenology and not on pathophysiology. Data are presented showing that psychiatric patients reveal consistent quantitative electroencephalographic abnormalities, such that they can be separated from normals and from each other. Clustering these pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Cancro, Robert, E. Roy, John, Chabot, Robert, Prichep, Leslie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Les Laboratoires Servier 2002
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181688/
https://www.ncbi.nlm.nih.gov/pubmed/22034254
_version_ 1782212789936324608
author Cancro, Robert
E. Roy, John
Chabot, Robert
Prichep, Leslie
author_facet Cancro, Robert
E. Roy, John
Chabot, Robert
Prichep, Leslie
author_sort Cancro, Robert
collection PubMed
description Psychiatric diagnosis suffers from being based on phenomenology and not on pathophysiology. Data are presented showing that psychiatric patients reveal consistent quantitative electroencephalographic abnormalities, such that they can be separated from normals and from each other. Clustering these pathophysiological groupings reveals an underlying variability, which permits useful subtyping. Data are presented relating subtyping to pharmacological treatment.
format Online
Article
Text
id pubmed-3181688
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher Les Laboratoires Servier
record_format MEDLINE/PubMed
spelling pubmed-31816882011-10-27 Subtyping of psychiatric disorders: implications for drug development Cancro, Robert E. Roy, John Chabot, Robert Prichep, Leslie Dialogues Clin Neurosci Clinical Research Psychiatric diagnosis suffers from being based on phenomenology and not on pathophysiology. Data are presented showing that psychiatric patients reveal consistent quantitative electroencephalographic abnormalities, such that they can be separated from normals and from each other. Clustering these pathophysiological groupings reveals an underlying variability, which permits useful subtyping. Data are presented relating subtyping to pharmacological treatment. Les Laboratoires Servier 2002-12 /pmc/articles/PMC3181688/ /pubmed/22034254 Text en Copyright: © 2002 LLS http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Research
Cancro, Robert
E. Roy, John
Chabot, Robert
Prichep, Leslie
Subtyping of psychiatric disorders: implications for drug development
title Subtyping of psychiatric disorders: implications for drug development
title_full Subtyping of psychiatric disorders: implications for drug development
title_fullStr Subtyping of psychiatric disorders: implications for drug development
title_full_unstemmed Subtyping of psychiatric disorders: implications for drug development
title_short Subtyping of psychiatric disorders: implications for drug development
title_sort subtyping of psychiatric disorders: implications for drug development
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181688/
https://www.ncbi.nlm.nih.gov/pubmed/22034254
work_keys_str_mv AT cancrorobert subtypingofpsychiatricdisordersimplicationsfordrugdevelopment
AT eroyjohn subtypingofpsychiatricdisordersimplicationsfordrugdevelopment
AT chabotrobert subtypingofpsychiatricdisordersimplicationsfordrugdevelopment
AT prichepleslie subtypingofpsychiatricdisordersimplicationsfordrugdevelopment

Ejemplares similares